Scientific ReportsSeptember 24, 2026Giammarco di Gregorio, Basset Sophia, Harjot Manmohan et al.
Abstract Depression and anxiety affect one in five adults and vary across the lifespan; while prevalence generally declines with age until midlife, later life is marked by a re-emergence of symptoms. Although clinical trials suggest classic psychedelics (e.g., psilocybin, LSD) and non-classic psychedelics (e.g., MDMA, ketamine) may alleviate these symptoms, it remains unclear how these...
Research SquareMarch 10, 2026Giammarco di Gregorio, Sophia Basset, Harjot Manmohan et al.
preprint
Abstract Depression and anxiety affect one in five adults, with age affecting prevalence. While clinical trials suggest classic psychedelics (e.g., psilocybin, LSD) and non-classic psychedelics (e.g., MDMA, ketamine) may alleviate these symptoms, it remains unclear how these relationships function in naturalistic settings or how they vary across the lifespan. We conducted a cross-sectional...